Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PCL 016

Drug Profile

PCL 016

Alternative Names: NV 02; NVTL 0001; PCL-016

Latest Information Update: 31 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novactyl
  • Developer Novactyl; Upsher-Smith
  • Class Antiacnes; Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne
  • No development reported Herpes simplex virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections in USA (Topical)
  • 27 May 2004 Data presented at the 65th Annual Meeting of The Society for Investigative Dermatology (SID-2004) have been added to the adverse events and Skin Disorders therapeutic trials sections
  • 14 Nov 2002 Upsher-Smith Laboratories has an exclusive worldwide licence for the development and commercialisation of PCL 016 for HSV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top